Topical glycopyrrolate provides comparable outcomes as Botox for facial hyperhidrosis: Study

Published On 2022-06-30 14:30 GMT   |   Update On 2022-06-30 14:31 GMT

Egypt: Topical glycopyrrolate 2% was shown to be equally effective to Botulinum toxin A for the treatment of facial hyperhidrosis (HH) with faster onset but shorter duration of action, according to a study. The study was published in Dermatologic Surgery on June 17, 2022. Facial hyperhidrosis is a common problem that has both cosmetic and psychological impacts and interferes with quality...

Login or Register to read the full article

Egypt: Topical glycopyrrolate 2% was shown to be equally effective to Botulinum toxin A for the treatment of facial hyperhidrosis (HH) with faster onset but shorter duration of action, according to a study. The study was published in Dermatologic Surgery on June 17, 2022. 

Facial hyperhidrosis is a common problem that has both cosmetic and psychological impacts and interferes with quality of life. There is an availability of a wide range of treatment options for HH, however, finding the most effective and yet safe, tolerable option is the main target. Considering this, Shrook Khashaba, Zagazig University, Zagazig, Egypt, and colleagues set out to investigate and compare the clinical efficacy, safety, and tolerability of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in the treatment of facial HH in an open-label clinical trial. 

For this purpose, the researchers included 24 patients with primary facial HH. The patients were randomly divided into two groups: Group A included patients treated with intradermal Botulinum toxin A injection and Group B included patients treated with topical glycopyrrolate gel 2%. 

Before and after the treatment, a starch iodine test was performed to assess the response, along with the Dermatology Life Quality Index (DLQI), Hyperhidrosis Disease Severity Scale, and patient satisfaction. 

Key findings include:

  • Both modalities showed complete response in 75% of cases with a longer duration of action in the botulinum toxin group up to 6 months.
  • Side effects were minor and temporary.
  • Both Hyperhidrosis Disease Severity Scale and DLQI showed statistically significant improvement after treatment.

"We found that topical glycopyrrolate 2% showed comparable results to Botulinum toxin A in facial HH treatment" the authors concluded. 

"Glycopyrrolate has a faster onset of action but requires continuous treatment, while intradermal Botulinum has a slower onset of action and longer duration of action," they wrote. 

Reference:

Nofal, Eman MD; Salem, Somaia MSc; Khashaba, Shrook A. MD* Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature, Dermatologic Surgery: June 17, 2022 - Volume - Issue - 10.1097/DSS.0000000000003490 doi: 10.1097/DSS.0000000000003490

Tags:    
Advertisement
Article Source : Dermatologic Surgery

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News